Infections

All Conditions

Symptoms and General Pathology

Neoplasms

Heart and Blood Diseases

Diseases and Abnormalities at or Before Birth

Rare Diseases

Communicable Diseases

Sarcoma

Cardiomyopathies

Virus Diseases

Herpesviridae Infections

Cardiomyopathy, Dilated

Sarcoma, Kaposi

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Heart Diseases

DNA Virus Infections

Neoplasms, Vascular Tissue

Cardiomegaly

Laminopathies

Genetic Diseases, Inborn

Soft Tissue Sarcoma

Dilated Cardiomyopathy

Kaposi Sarcoma

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Sirolimus

Anti-Bacterial Agents

Antibiotics, Antitubercular

Clotrimazole

Miconazole

Antifungal Agents

Immunosuppressive Agents

Immunologic Factors

patients with dilated cardiomyopathy infected with Kaposi sarcoma-associated virus to receive standard DCM therapy

patients with dilated cardiomyopathy infected with Kaposi sarcoma-associated virus to receive sirolimus (at a dose of 2 mg once daily) in addition to standard DCM therapy

Yanru Zhao, Doctor

Dao Wen Wang, Doctor

Evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with Kaposi Sarcoma-associated virus -- a multicenter randomized controlled study.

Dilated cardiomyopathy (DCM), defined as left ventricular or biventricular dilation and systolic dysfunction in the absence of either pressure or volume overload or coronary artery disease sufficient to explain the dysfunction, is associated with poor cardiovascular outcome and poor prognosis. Inflammation, activated by viral persistence, was considered as a key trigger factor of cardiac remodeling and thereby the development of DCM. As a risk factor for DCM, Kaposi's sarcoma-associated herpes virus (KSHV) inhibits the type I IFN signaling pathway and thereby aggravates known cardiotropic viruses-induced cardiac dysfunction and inflammatory infiltration. Activated mTOR signaling pathway is a typical feature of KSHV-infected cells, which is the most effective therapeutic target of diseases caused by KSHV infection. Sirolimus, a mTOR inhibitor, is a drug that can effectively treat the KSHV-infected diseases and suppresses the replication of KSHV.Therefore, multicenter large randomized controlled trials are needed to verify the efficacy of sirolimus on patients with DCM infected with KSHV.

This study aimed to evaluate the effiects of sirolimus on the clinical outcomes of patients with DCM infected with KSHV and provide theoretical evidence for the clinical application of sirolimus in these patients.

The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus

Death from cardiovascular disease which includes coronary artery diseases, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease and carditis

The rate of heart trans plantation on patients with DCM when other medical or surgical treatments have failed

The readmission rate for cardiovascular diseases

The score of patients measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus	NCT06236022	Dilated Cardiom... Kaposi's Sarcom...	Sirolimus	18 Years - 70 Years	Tongji Hospital
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus	NCT06236022	Dilated Cardiom... Kaposi's Sarcom...	Sirolimus	18 Years - 70 Years	Tongji Hospital
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus	NCT06236022	Dilated Cardiom... Kaposi's Sarcom...	Sirolimus	18 Years - 70 Years	Tongji Hospital

Spots Global Cancer Trial Database for dilated cardiomyopathy